Panacea Biotech shares up 56% in six sessions; Here are the latest developments – CNBC TV18
Panacea Biotec is a key partner in the consortium as the developer of DengiAll, a tetravalent live-attenuated dengue vaccine candidate targeting all four dengue virus serotypes and currently in late-stage development in India. Shares of Panacea Biotec surged more than 15% in intraday trade on Tuesday, June 9, after the company announced the launch of an European Union-funded project aimed…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
